LEXARIA BIOSCIENCE CORP.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $705.9K | $464.3K | $226.2K | $255.4K | $722.7K | $314.8K | $222.6K | $433.3K |
| Cost of Revenue | $2.7K | $4.8K | $31.5K | $71.8K | $175.3K | $99.4K | $22.9K | $25.2K |
| Gross Profit | $703.2K | $459.5K | $194.7K | $183.6K | $547.4K | $215.4K | $199.7K | $408.1K |
| Gross Margin | 99.6% | 99.0% | 86.1% | 71.9% | 75.7% | 68.4% | 89.7% | 94.2% |
| Operating Expenses | ||||||||
| Research & Development | $8.2M | $2.4M | $3.7M | $1.8M | $1.3M | $387.1K | $555.7K | $492.9K |
| SG&A Expense | $4.3M | $3.9M | $3.1M | $5.0M | $5.0M | $4.0M | $297.2K | $217.7K |
| Operating Income | $-11.9M | $-5.8M | $-6.5M | $-6.6M | $-5.7M | $-4.0M | $-4.2M | $-6.6M |
| Operating Margin | -1,683.0% | -1,239.2% | -2,888.5% | -2,591.7% | -786.8% | -1,266.6% | -1,868.0% | -1,525.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-11.9M | $-5.8M | $-6.7M | $-7.4M | $-4.2M | $-4.0M | $-4.2M | $-6.6M |
| Income Tax Expense | — | — | — | $0 | $6.1K | $2.3K | $17.7K | $0 |
| Net Income | $-11.9M | $-5.8M | $-6.7M | $-7.3M | $-4.0M | $-4.1M | $-4.2M | $-6.6M |
| Net Margin | -1,686.0% | -1,248.2% | -2,946.4% | -2,846.3% | -557.2% | -1,297.6% | -1,868.0% | -1,525.4% |
| EPS (Basic) | — | — | — | — | $-0.95 | $-1.47 | $-0.05 | $-0.09 |
| EPS (Diluted) | $-0.66 | $-0.47 | $-1.01 | — | $-0.95 | $-1.47 | $-0.05 | $-0.09 |
| Shares Outstanding (Basic) | — | — | — | 6.0M | 5.7M | 90.0M | 78.8M | 77.1M |
| Shares Outstanding (Diluted) | 18.0M | 12.4M | 6.6M | 6.0M | 5.7M | 90.0M | 78.8M | 77.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |